Clinical Efficacy and Safety Evaluation of Advanced NSCLC Treated by Gemcitabine Combined Platin or Cisplatin

Abstract

Abstract: Objective To compare the two gemcitabine related chemotherapy regimens(gemcitabine (GEM) in combination with cisplatin (DDP) or nedaplatin(NDP)) on non-small cell lung cancer(NSCLC), analyze the differences of curative effect and adverse drug reactions (ADR), and provide reference to clinical individualized regimen. Methods The 58 cases diagnosed with NSCLC patients in Xuzhou Medical University Affiliated Hospital between January 2015 and April 2017 were divided into 2 groups, 30 cases of NDP combined with GEM (GN), 28 cases of DDP combined with GEM (GP), treatment cycles within 21 days. Recorded ADR of each cycle of chemotherapy regimens; evaluated curative effect using CT when the third cycle chemotherapy had been finished, then analyzed the adverse reactions and curative effect between the two regimens. Results GN regimen effective rate is 43.33%, GP is 42.86%, there is no significant difference (P>0.05). Gastrointestinal symptoms incidences of NP are lower than GP regimens (P<0.05), and there are no statistical significant differences in decreasing of NEUT, WBC, HGB and PLT, liver toxicity, kidney toxicity(P>0.05). Conclusion Curative effect of GN is similar to GP, and the gastrointestinal reaction of GN is slighter, good tolerance, without hydration treatment. From the effectiveness and safety considerations, GN scheme is comparable with GP for treatment options.

Key words: gemcitabine, cisplatin, nedaplatin, non-small-cell lung cancer, adverse drug reactions

CLC Number:

R979.11

XUE Yan-hong, WANG Lai-cheng, HU Li-li,*, YANG Bo. Clinical Efficacy and Safety Evaluation of Advanced NSCLC Treated by Gemcitabine Combined Platin or Cisplatin[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 136-139.

References

[1] 刘晓, 贾燕花, 张可, 等. 非小细胞肺癌EML4-ALK靶向药物耐药机制及逆转耐药的研究进展[J].中国新药杂志, 2016, 25(9): 1018-1023.
[2] 旷琛, 陈敏, 毛棉, 等. 埃克替尼治疗晚期非小细胞肺癌的系统评价[J]. 中国药房, 2016, 27(9): 1219-1222.
[3] 刘淑, 郑玉龙, 王伟, 等. 吉西他滨联合奈达铂与吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的临床研究[J]. 现代肿瘤医学, 2010, 18(4): 722-724.
[4] 刘淑俊, 邸立军, 王洁, 等. 国产盐酸吉西他滨治疗晚期非小细胞肺癌的Ⅱ期临床研究[J].中华肿瘤杂志, 2003, 25(6): 584-586.
[5] 罗扬, 张湘茹. 吉西他滨治疗晚期非小细胞肺癌的现状[J]. 中国癌症杂志, 2002, 11(1): 74-80.
[6] 韦灵玉, 邱晓春, 周彦来, 等. 我院907例抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2017, 14 (4): 242-245.
[7] Parra H J S, Cavina R, Antonelli G, et al. Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): Results of a randomized phase II study[J]. Lung Cancer, 2000, 29(1): 48-48.
[8] 陈颖, 林昊. 84例奈达铂致不良反应分析[J]. 中国药物警戒, 2012, 9(11): 691-692.
[9] 王健, 曹东, 顾文静, 等. WHO标准与RECIST标准评价恶性肿瘤治疗效果的比较[J].中国基层医药, 2013, 20(5): 652-654.
[10] 李继东, 王舒, 肖永久, 等. 国产奈达铂联合吉西他滨治疗晚期非小细胞肺癌[J]. 实用医学杂志, 2008, 24(5): 811-812.
[11] 沈凡, 李会萍. 吉西他滨联合顺铂治疗晚期非小细胞肺癌临床观察[J]. 中华肿瘤防治杂志, 2015，22(b11): 100-101.
[12] Morabito A, Gebbia V, Maio M D, et al. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study[J]. Lung Cancer, 2013, 81(1): 77-83.
[13] 王莉, 刘汉锋, 蔡正文, 等. 奈达铂与顺铂对人肝肾细胞损伤作用的对比[J]. 广东医学, 2012, 33(6): 736-738.
[14] 成卫, 王彩英. 吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效评价[J]. 实用临床医药杂志, 2012, 16(19): 89-90.
[15] 路太英, 樊青霞, 王留兴, 等. 改良水化法对以顺铂为主方案化疗所致肾毒性的影响[J].医药论坛杂志, 2006, 27(18): 79-80.
[16] 雷琳, 黄亚平, 张凌云, 等. 奈达铂联合吉西他滨治疗中晚期非小细胞肺癌的临床观察[J]. 实用癌症杂志, 2013, 28(2): 166-167.